2269. Deputy Pádraig O'Sullivan asked the Minister for Health the process by which standard oral nutritional supplements are assessed and assigned to List A or List B for reimbursement under the community drug schemes; the criteria applied; the body responsible for making these determinations; and if she will make a statement on the matter. [43515/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Pádraig O'Sullivan under the heading Medicinal Products.
75 questions match, newest first.
2270. Deputy Pádraig O'Sullivan asked the Minister for Health the number of prior reimbursement approval applications for List B standard oral nutritional supplements received by the Primary Care Reimbursement Service in each year since 2021; the number approved and refused respectively; the average processing time for such applications; and if she will make a statement on the matter. [43516/26]
2271. Deputy Pádraig O'Sullivan asked the Minister for Health whether she will review the requirement for six-monthly renewal of reimbursement approval for List B standard oral nutritional supplements, given the administrative burden this places on general practitioners, dietitians and hospital clinicians; and if she will make a statement on the matter. [43517/26]
2359. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that have been approved for reimbursement in each of the years 2021 to 2025, in tabular form; and if she will make a statement on the matter. [43769/26]
2360. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that have been refused for reimbursement in each of the years 2021 to 2025, in tabular form; and if she will make a statement on the matter. [43770/26]
2361. Deputy Pádraig O'Sullivan asked the Minister for Health the number of applications for new drugs that are currently under consideration for reimbursement; and if she will make a statement on the matter. [43771/26]
2362. Deputy Pádraig O'Sullivan asked the Minister for Health the drugs that will be considered for reimbursement at the June 2026 meeting of the NCPE drugs group; and if she will make a statement on the matter. [43772/26]
2364. Deputy Pádraig O'Sullivan asked the Minister for Health the status of the progress of givinostat through the drug reimbursement process; and if she will make a statement on the matter. [43774/26]
2365. Deputy Pádraig O'Sullivan asked the Minister for Health if she is satisfied with the NCPEs role within the drug reimbursement process and that appropriate governance and best practice is in situ in its activities; and if she will make a statement on the matter. [43775/26]
2366. Deputy Pádraig O'Sullivan asked the Minister for Health her views on whether it is appropriate for members of the NCPE to be engaging in public commentary while deliberations on certain drugs are currently being undertaken; and if she will make a statement on the matter. [43776/26]
2368. Deputy Pádraig O'Sullivan asked the Minister for Health if the State remains on course to achieve the 180-day review timeline for new medicines and new uses of existing medicines committed to under schedule four of the Framework agreement on the supply and pricing of medicines, given that according to the EFPIA patients W.A.I.T. indicator 2025 survey the average time to access new medicines in Ireland has risen…
280. Deputy Pádraig O'Sullivan asked the Minister for Health the proportion of innovative oncology medicines approved at European level that are currently available and reimbursed in Ireland; the reason this proportion remains at approximately 25% given that the 180-day reimbursement timeline has been a legislative requirement under the Health Act 2013 for over a decade; the accountability measures that will be put i…
281. Deputy Pádraig O'Sullivan asked the Minister for Health the current status of the proposed expansion of the drugs group to include patient and public interest members as committed to under the new framework agreement on medicines published in March 2026; whether an expression of interest process has been initiated to identify suitable patient representatives; given that no such process has been publicly announce…
282. Deputy Pádraig O'Sullivan asked the Minister for Health if she will provide a specific update on the design and implementation of an early access scheme for medicines in Ireland, as referenced in the new framework agreement on medicines published in March 2026; whether a pilot has been announced or a design process initiated that includes patients and clinicians; the timeline within which a functioning early acc…
291. Deputy Pádraig O'Sullivan asked the Minister for Health the current state of Ireland’s preparedness for utilising the EU’s Joint Clinical Assessments, JCA, on clinical trial data in evaluations by the HSE and the National Centre for Pharmacoeconomics (NCPE); when she expects such JCA’s to be applied to such evaluations; and if she will make a statement on the matter. [40695/26]
292. Deputy Pádraig O'Sullivan asked the Minister for Health the guidance that has been issued to Irish marketing authorisation holders regarding the process, timelines, and expectations for considering the EU’s Joint Clinical Assessment (JCA) by the HSE and the National Centre for Pharmacoeconomics (NCPE); the way JCA reports will be factored into the reimbursement recommendations for treatments; and if she will mak…
1099. Deputy Pádraig O'Sullivan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy; and if she will make a statement on the matter. [38709/26]
1215. Deputy Pádraig O'Sullivan asked the Minister for Health if she will outline what steps her Department is taking to address the fact that brexpiprazole and lurasidone, two antipsychotic medicines now recommended as first-line treatment options for females with first-episode psychosis in the first international clinical guideline of its kind published in March 2026, are currently licensed in Ireland but not reimb…
829. Deputy Pádraig O'Sullivan asked the Minister for Health the steps her Department is taking to ensure continuity of medication management supports for adults and children with disabilities and cognitive impairment, particularly in respect of the safe use of monitored dosage systems where these are clinically indicated; and if she will make a statement on the matter. [33043/26]
830. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has carried out, or commissioned, any assessment of the impact on persons with disabilities of the requirement to privately fund pharmacist-prepared blister packs and monitored dosage systems where such supports are recommended on safety grounds; and if she will make a statement on the matter. [33044/26]
1190. Deputy Pádraig O'Sullivan asked the Minister for Health the average length of time taken by the HSE Drugs Group to issue a final reimbursement decision following receipt of a National Centre for Pharmacoeconomics Health Technology Assessment in each of the past five years; whether her Department has assessed the impact of these timelines on patients with rare diseases; and if she will make a statement on the ma…
1191. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has considered introducing a managed access scheme or interim reimbursement pathway for orphan and rare disease medicines that have received European Medicines Agency authorisation but are awaiting a final HSE reimbursement decision; and if she will make a statement on the matter. [33126/26]
1192. Deputy Pádraig O'Sullivan asked the Minister for Health given that European data indicates significant variability between member states in the reimbursement of orphan medicines for rare diseases, the steps her Department is taking to align Ireland's rare disease reimbursement framework with comparable EU jurisdictions; and if she will make a statement on the matter. [33127/26]
1193. Deputy Pádraig O'Sullivan asked the Minister for Health in light of the Health Products Regulatory Authority confirming that over 750,000 dosage units of falsified and illegal medicines were detained in 2025, with a thirty-fold increase in unauthorised GLP-1 type products, whether her Department has assessed the extent to which restricted access to authorised, reimbursed GLP-1 treatments through the HSE is driv…
1194. Deputy Pádraig O'Sullivan asked the Minister for Health the public awareness measures her Department and the HPRA are undertaking to alert the public to the serious health risks associated with sourcing prescription medicines through unauthorised online channels, particularly in respect of GLP-1 medicines marketed as drops or microneedle patches; and if she will make a statement on the matter. [33129/26]